ProQuad

Sponsor:

Merck Sharp & Dohme (Australia)

Administration route:

Intramuscular injection, Subcutaneous injection

Vaccine group:

Combination vaccines

Registered for use in children aged 12 months to 12 years.

— measles-mumps-rubella-varicella combination vaccine

Lyophilised powder in a monodose vial with a pre-filled diluent syringe.

Each 0.5 mL reconstituted dose contains:

≥10^3.00 culture infectious dose 50% (TCID₅₀) of live attenuated measles virus (Enders’ attenuated Edmonston strain)
≥10^4.30 TCID₅₀ of live attenuated mumps virus (Jeryl Lynn B level strain)
≥10^3.00 TCID₅₀ of live attenuated rubella virus (Wistar RA 27/3 strain)
≥10^3.99 plaque-forming units of live attenuated varicella-zoster virus (Oka/Merck strain)
20 mg sucrose
11 mg hydrolysed porcine gelatin
2.5 mg urea
16 mg sorbitol
0.38 mg monosodium L-glutamate
0.25 mg recombinant human albumin
5 µg neomycin
residual components of MRC-5 cells
0.5 µg bovine serum albumin

For full details, refer to the product information and consumer medicine information sheets for ProQuad vaccine available on the TGA website.

Last updated:

12 April 2019

Last reviewed:

12 April 2019

Definitions